Invention Grant
- Patent Title: Combination therapy of Axl inhibitor and EGFR tyrosine kinase inhibitor
-
Application No.: US17734875Application Date: 2022-05-02
-
Publication No.: US11806339B2Publication Date: 2023-11-07
- Inventor: Takeshi Jimbo
- Applicant: Daiichi Sankyo Company, Limited
- Applicant Address: JP Tokyo
- Assignee: Daiichi Sankyo Company, Limited
- Current Assignee: Daiichi Sankyo Company, Limited
- Current Assignee Address: JP Tokyo
- Agency: Fish & Richardson P.C.
- Priority: JP 17058858 2017.03.24
- Main IPC: A61K31/444
- IPC: A61K31/444 ; A61P35/00 ; A61K31/506
Abstract:
The present invention provides a medicament comprising a compound represented by general formula (1) which has Axl inhibitory activity, and an EGFR tyrosine kinase inhibitor in combination, and a method for treating cancer using this combination. The present invention provides an excellent medicament and method for treating cancer which is highly effective for inhibiting resistance to an EGFR tyrosine kinase inhibitor in cancer treatment, and causes less adverse reactions such as weight loss.
Public/Granted literature
- US20220331302A1 COMBINATION THERAPY OF AXL INHIBITOR AND EGFR TYROSINE KINASE INHIBITOR Public/Granted day:2022-10-20
Information query
IPC分类:
